Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (NYSE: AZN) declared on Wednesday that it has received European Commission approval for Trixeo Aerosphere as a maintenance treatment for asthma in patients aged 12 and over who are inadequately controlled on medium-dose inhaled corticosteroid and long-acting beta2-agonist therapy. Trixeo is the first triple-combination therapy approved in the EU for this population regardless of exacerbation history.
This approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use and was supported by Phase III KALOS and LOGOS trials. Trixeo demonstrated statistically significant improvements in lung function and, in pooled analysis, a significant reduction in the annualised rate of severe asthma exacerbations versus dual therapy.
The trials involved approximately 4,300 patients and identified no new safety or tolerability signals. Trixeo is marketed as Breztri Aerosphere in the US, China and Japan and is also approved for asthma in the US and Japan, while regulatory reviews are ongoing in other markets.
Trixeo Aerosphere is also approved for chronic obstructive pulmonary disease in more than 90 countries and was prescribed to more than 6.8 million patients globally in 2025.
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
Sichuan Kelun-Biotech announces Phase III OptiTROP-Lung04 study results at 2026 ESMO
Bio-Thera reports promising BAT8008 - BAT1308 combination lung cancer clinical data at ESMO 2026
Zai Lab reports promising Phase 1b results for zocilurtatug pelitecan in small cell lung cancer
IHI and Bristol Myers Squibb launch initiative to expand cancer clinical trial access
Oracle partners AstraZeneca for AI-enabled healthcare innovation
GSK reports 61% response rate for investigational lung cancer drug
Omeros receives negative EU opinion on narsoplimab after re-examination
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer
Sophos IRB and ALCMI partner to support lung cancer research
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK